11/30/2020 1:02:28 AM
Regeneron: EC Extends Marketing Authorization For Dupixent For Children Aged 6-11 Yrs With Severe Atopic Dermatitis
11/5/2020 6:31:31 AM
Regeneron Q3 GAAP EPS $7.39 And Non-GAAP EPS $8.36
10/30/2020 9:14:08 AM
Regeneron Receives Recommendation From IDMC For REGN-COV2 Antibody Cocktail Treatment Trials For COVID-19
10/29/2020 9:53:02 AM
European Patent Office Rules In Favor Of Sanofi And Regeneron Concerning Praluent
10/29/2020 7:31:11 AM
Regeneron: FDA Accepts For Priority Review Libtayo For Advanced Non-small Cell Lung Cancer With PD-L1 Expression Of =50%
10/28/2020 5:05:34 PM
Regeneron: Phase 2/3 Seamless Trial In COVID-19 Outpatient Setting On REGN-COV2 Met Primary, Key Secondary Endpoints
10/26/2020 8:07:55 AM
Regeneron, Sanofi Announce Addl Positive Results From Part A Of A Pivotal Phase 3 Trial Of Dupixent
10/16/2020 8:00:57 AM
Regeneron Pharma: CHMP Recommends Approval Of Dupixent For Children Aged 6 To 11 Years With Atopic Dermatitis